Shares in Tripos began to climb this week following news that the company had hired a financial advisor to help it "explore various strategic alternatives," and continued their ascent after the company disclosed an informatics collaboration with Wyeth Pharmaceuticals worth approximately $5 million.
At press time, the company's stock had risen 28.4 percent over the course of the week — a welcome boost after several years of lackluster performance.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
